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the Orange Free State.'· Although the prevalence of HIV
positivity is rising, the lower prevalence found in our study in
1991 might also be attributed to some degree to the study
population comprising women in their reproductive years
(18 - 49 years), all of whom might not have been as sexually
active as the pregnant population.
In conclusion, extremely high prevalences of Trichomonas
vaginalis vaginitis and syphilis were documented. The high
rate of unemployment in this population is probably a
contributing factor. Although the prevalence of HIV infection
was high, it was similar to that found in other parts of South
Africa. Among rural women the knowledge of AIDS was
inadequate, particularly with regard to the methods of
transmission and the lack of a cure. Earnest attention needs
to be given to the combating of these sexually transmitted
diseases, particularly syphilis and HIV infection.
We wish to thank all the professional nurses for their
contribution, Mrs I. Venter for typing the manuscript, and
Mr B. de Winnaar for his contributions. This study was
supported by the National Cancer Society of South Africa
and the Provincial Administration of the Orange Free State.
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Developments in the treatment of stage I testicular non-
seminomatous germ cell tumours have aimed primarily at
reducing morbidity since the introduction of
retroperitoneal lymph node dissection. Surveillance after
orchidectomy, Le. follow-up alone with chemotherapy only
for relapsed disease, was found to be logistically and
psychologically taxing for patients. Risk factors for relapse
were, however, identified from analyses of tumour
histology of the orchidectomy specimen.
Between September 1988 and April 1992, 20 patients
with clinical stage I testicular non-seminomatous germ cell
tumours and a relatively high risk of relapse were entered
into a prospective study of adjuvant chemotherapy. The
chemotherapy regimen consisted of 2 cycles of cisplatin,
etoposide and bleomycin. Each cycle of chemotherapy
lasted 3 days.
There have been no relapses at a median follow-up of
31 months (range 12 - 53 months). Acute and late toxicity
have been modest. We have found adjuvant chemotherapy
to be effective after orchidectomy in patients with stage I
disease with adverse prognostic factors for relapse.
S Atr Med J 1994; 84: 605-607.
Testicular tumours constitute 1 - 2% of all malignancies in
men and are the most common malignancy in the
economically active age group of 15 - 35 years. 1 They are
divided approximately equally into seminomas and non-
seminomatous germ cell tumours (NSGCTs). Seminomas are
radiosensitive and patients with stage I disease (clinically
localised to the testis) have been treated since the 1920s
with retroperitoneal irradiation.2 .3 Patients with stage I NSGCT
have undergone retroperitoneal lymph node dissection
(RPLND) in many centres since the 1960s.< The aim of
RPLND is to stage patients accurately; it is also curative in a
proportion of patients with lymph node metastases.
The introduction of cisplatin combination chemotherapy in
the 1970s resulted in cures in the majority. of patients with
metastatic NSGCT.5.6 This led to a re-evaluation of the need
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for RPLND in patients with stage I NSGCT. Surveillance
studies were undertaken with follow-up only after
orchidectomy and chemotherapy for patients with relapsed
disease.' This approach resulted in cure rates of close to
100%, but was found to be logistically and psychologically
taxing for patients.·
Analysis of tumour histology in the orchidectomy
specimen in patients entered into surveillance studies led to
the identification of risk factors for relapse._A prospective
study of adjuvant chemotherapy was undertaken in patients
with stage I testicular cancer with a relatively high risk of
relapse. The chemotherapy regimen used had been
designed to minimise toxicity.-
Materials and methods
Twenty patients with clinical stage I NSGCT were treated
with adjuvant chemotherapy between September 1988 and
April 1992 at Groote Schuur Hospital, Cape Town, Provincial
Hospital, Port Elizabeth and Frere Hospital, East London.
The patients had all undergone an orchidectomy and
staging investigation included negative serum tumour
markers (a-fetoprotein and 13-human choriogonadotrophin),
chest radiographs and compute.d tomography (CT) of the
abdomen. The median patient age was 25 years (range
20 - 35 years).
Adverse prognostic factors for relapse are determined
from the histological features of the orchidectomy specimen
according to the findings of the British Medical Research
Council. These were the presence of undifferentiated
carcinoma (embryonal carcinoma), the absence of yolk SaG
tumour and the presence of vascular or lymphatic inv<;ision.
There were 2 adverse prognostic factors present in 2
patients and either 3 or 4 such factors in the remainder.
Adjuvant chemotherapy consisted of 2 cycles of
combination chemotherapy given 3 weeks apart. -Each cycle
consisted of 3 daily injections of cisplatin (35 mg/m2),
etoposide (120 mg/m2) and bleomycin (15 mg over 7 hours).
Patients were hydrated with a minimum of 3 litres of fluid
per day.
Results
There were no relapses at a minimum follow-up of 12
months in all patients. The median length of follow-up was
31 months (range 12 - 53 months).
Toxicity was minimal with no acute grade 3 or grade 4
leucopenia or thrombocytopenia. There have been no acute
or late episodes of renal or pulmonary toxicity.
Discussion
Developments in the treatment of stage I NSGCT since the
introduction of RPLND have aimed primarily at reducing
morbidity. RPLND may result in failure of semen emission
(ejaculatory impotence) because of dissection of the
sympathetic nerves overlying the major vessels.
The introduction of effective chemotherapy for NSGCT
resulted in MRC surveillance studies of patients with stage I
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NSGCT. The 4-year relapse rate was 32% and virtually all
relapsing patients were saved with chemotherapy.' However,
surveillance was found to be logistically demanding, and
required multiple follow-up evaluations, including abdominal
CT; it was also stressful to patients afraid of possible
relapse.· Some patients even reported relief at the diagnosis
of metastatic disease as they could now receive definitive
therapy.
Review of the histology of the orchidectomy specimen
allowed for the identification of adverse prognostic factors
for relapse. The 2-year relapse-free rate for patients with 0,
1,2 and 3/4 adverse prognostic factors present was 100%,
91 %, 75% and 52% respectively.- The proportion of all
cases according to the relapse factors above were 3%, -
31 %, 34% and 42%. Patients with a high risk of relapse, .
especially those with 3 or 4 adverse factors, are particularly
suitable candidates for adjuvant chemotherapy. Patients
with 2 adverse factors may choose to have adjuvant therapy
even though their chance of relapse is lower.
Adjuvant chemotherapy has been found to be effective in
patients with stage 11 disease undergoing RPLND.'o In a
prospective trial of 195 patients, the relapse rate for patients
treated with RPLND alone was 49% and that for patients
receiving 2 cycles of chemotherapy was 0%. The toxicity
was also relatively low. It is noteworthy that toxicity from 4
cycles of chemotherapy is worse than from 2 cycles of
chemotherapy.·
The chemotherapy used has a relatively low toxicity. The
duration of hospitalisation per cycle of chemotherapy is
reduced from 5 to 3 days and the use of bleomycin by
infusion over 3 days may be associated with reduced
pulmonary toxicity.
The MRC study of adjuvant therapy used 2 cycles of
5-day cisplatin combination chemotherapy. There is one
report of adjuvant therapy for testicular cancer where 3
CYcles of the more toxic PVB regimen" (cisplatin, vinblastine
and bleomycin) are given. No relapses were seen in 30
patients at a median follow-up of 31 months (range 14 - 60+
months).'2
We have found adjuvant chemotherapy after orchidectomy
effective in patients with stage I disease and adverse
prognostic factors for relapse. Further follow-up is being
undertaken. Adjuvant chemotherapy is well tolerated and
associated with minimal morbidity. Should similar findings
emerge from the British MRC and other studies, we believe
that it will become the treatment of choice in these patients.
We thank the National Cancer Association of South Africa
for financial support, Mrs J. Wilmott for gathering data and
Mrs D. Godley for preparing the manuscript.
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Patients with severe pre-eclampsia were randomised to
receive magnesium sulphate according to an
intramuscular (IM) (N =9) or an intravenous (IV) (N =8)
regimen. The IM regimen consisted of a loading dose of
14 g (4 g IV and 10 g IM) followed by 5 g 4-hourly. Patients
given the IV regimen received a 6 g IV loading dose
followed by a maintenance infusion of 2 g/h. Clinical
outcome, laboratory parameters and serum magnesium
levels were recorded for both groups.
There were no significant differences between groups
with regard to clinical outcome of either mother or child.
Similar average serum magnesium concentrations were
produced by the regimens the only significant difference
was that fluctuations in magnesium levels were greater
with the IM than the IV regimen. None of the patients had
seizures despite levels mostly below 2 mmol/l.
S Atr Med J 1994; 84: 607-610.
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Magnesium sulphate (MgSO,) is the anticonvulsant most
widely used in the USA and South Africa for the
management of severe pre-eclampsia. It is given
parenterally, usually according to one of two popular
regimens: the intramuscular (IM) regimen introduced by
Pritchard' and a continuous intravenous (IV) infusion
described by Zuspan! Sibai et a/.3 have reported that lower
serum magnesium values are achieved with Zuspan's
regimen (maintenance dose 1g/h) than with Pritchard's
regimen. Given that Sibai et al.' had previously found that 8
of 9 convulsing patients had low levels of serum magnesium
after receiving Zuspan's regimen, they concluded that an IV
maintenance dose of 1 g/h was insufficient to prevent the
occurrence of seizures in some pre-eclamptic patients. They
thus recommend an IV maintenance dose of 2 g/h.3
The purpose of this prospective study was to compare the
clinical outcome as well as the magnesium levels obtained
in the treatment of severe pre-eclampsia with the IM
regimen of Pritchard and an IV regimen with maintenance
doses of 2 g/h.
Subjects and methods
Seventeen women with severe pre-eclampsia and imminent
eclampsia were studied at King Edward VIII (KEH) Hospital
in Durban. This hospital is a tertiary referral centre for the
coastal region of Natal and serves an indigent population
from poor socio-economic conditions. Delivery of 14 000
high-risk patients is conducted each year and 18% of all
obstetric admissions have some degree of hypertension.
Patients eligible for the trial had proteinuria of at least 1+
assessed by a semiquantitative 'dipstick' method (Ames)
and diastolic blood pressures of 110 mmHg or more which
did not settle during a 4-hour observation period. Patients
with hypertension and proteinuria who had additional
symptoms or signs such as persistent headache, visual
disturbances, epigastric pain, increased patellar reflexes and
clonus, were considered to have impending eclampsia - 2
of the 8 women in the IV group and 4 of the 9 women in the
IM group.
After Ethics Committee approval was received, patients
were randomly allocated to receive either IM or IV MgSO,.
Those receiving the IM regimen (N = 9) were given 4 9
MgSO, in 200 ml normal saline as an infusion over 15
minutes and simultaneously given 5 9 MgSO, IM in each
buttock. Thereafter, every 4 hours an additional 5 g MgSO,
were given in alternate buttocks.
Eight patients received continuous IV MgS04. A loading
dose of 6 g in 200 ml normal saline was infused over 15
minutes, followed immediately by a maintenance dose of
2 g/dl/h given via a controlled infusion pump.
In all patients the patellar reflexes and respiratory rate
were noted every 4 hours. When either was suppressed, or
when the urine output was less than 30 ml/h over the
preceding 4 hours, MgSO, was discontinued. MgSO, was
discontinued after 24 hours of therapy, providing delivery
had occurred.
Obstetric management continued according to a standard
protocol previously described.5 If the diastolic blood
pressure reached 115 mmHg, then 6,25 mg dihydralazine in
10 ml normal saline was infused over a period of at least 5
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